David Werner and Nathan Berman are behind the historic project that appears to have serious structural concerns.

Pfizer stock currently trades at less than 9 times forward earnings while yielding more than 6%, making it one of the cheapest large-cap pharmaceutical stocks on the market. That immediately gets ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

WASHINGTON, March 11 (Reuters) - Pfizer (PFE.N), opens new tab, Teva and other major drugmakers have failed to persuade a federal judge to disqualify a former prosecutor who is representing private ...

Pfizer's dividend yield is so high at least in part because the stock has fallen more than 50% from its 2021 highs. There are a number of reasons for this fall from grace, but one very important one ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker of Ozempic and Wegovy. By Francesca Regalado The obesity drug developer ...

Pfizer $4.9 billion cash acquisition of Metsera, a clinical-stage biotech focused on next-generation obesity drugs, is more than another high-profile deal in pharma’s dealmaking spree. It signals a ...

Washington — Pfizer has agreed to offer significantly discounted prices for some prescription drugs for all American consumers and has committed to offer prescription medications to Medicaid at lower ...

President Donald Trump today, Sept. 30, announced TrumpRX, a new website for Americans to buy drugs, while he touted lower prices across Pfizer drugs, according to the Wall Street Journal. Trump ...

Sept 11 (Reuters) - A former government antitrust enforcer who oversaw price-fixing cases for U.S. states against major generic drugmakers should be barred from working on similar matters at his ...

Matthew Herper covers medical innovation — both its promise and its perils. Pfizer CEO Albert Bourla on Wednesday defended the development of Covid vaccinations, including Pfizer’s own, suggesting ...